Inarigivir soproxil 是一种先天免疫激动剂。 它还显示出针对耐药丙型肝炎病毒 (HCV) 变体的有效抗病毒活性。在基因型 1 HCV 复制子系统细胞中， HCV 1a/1b 的 EC50 为 2.2 和 1.0 μM。

Inarigivir soproxil is an agonist of innate immunity. It also displays effective antiviral activity against resistant hepatitis C virus (HCV) variants (EC50s of 2.2 and 1.0 μM for HCV 1a/1b in cells of genotype 1 HCV replicon systems).

Inarigivir soproxil is shown to inhibit HCV replication and the range of inhibition is comparable between genotypes 1a and 1b. Inarigivir soproxil is an oral modulator of innate immunity that is believed to act via the activation of the RIG-I and NOD2 pathways. Inarigivir soproxil demonstrates pan-genotypic antiviral activity against HCV. Inarigivir soproxil is active against DAA-resistant HCV variants. SB 9200 has broad-spectrum antiviral activity against RNA viruses including hepatitis C virus (HCV), norovirus, respiratory syncytial virus and influenza and has demonstrated activity against hepatitis B virus (HBV)[1].

942123-43-5

C25H34N7O13PS

703.62

SB9200

DMSO:102 mg/mL (144.96 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years